FOXP3 gene is associated with susceptibility to ischemic stroke in the Chinese population. 2024

Youpei Wang, and Tiru Shan, and Peipei Mao, and Yi Jiang, and Zhao Wang
Department of Geriatric Medicine, Qingdao Chengyang People's Hospital, Qingdao 266109, China.

OBJECTIVE Immunoinflammatory response plays an important role in the pathophysiological process of ischemic stroke (IS). Forkhead box P3 (FOXP3) is a master regulator for immune cells. Polymorphisms of FOXP3 gene might contribute to the susceptibility of IS. This study aimed to explore the association between FOXP3 gene polymorphisms (rs3761548 and rs2232365) and IS susceptibility in the Chinese Han population. METHODS Polymerase chain reaction and Sanger sequencing were used to detect the genotype of FOXP3 gene rs3761548 and rs2232365 polymorphisms. RESULTS Smoking, diabetes mellitus (DM), and HBP histories, higher TG and HDL-C levels were more frequently observed in IS patients than in controls. In comparison with rs3761548 GG genotype, GT genotype (OR = 1.573, 95 %CI = 1.030-2.402; adjusted: OR = 1.736, 95 %CI = 1.070-2.817) and GT + TT vs. GG model (OR = 1.581, 95 %CI = 1.0449-2.382; adjusted: OR = 1.720, 95 %CI = 1.074-2.755) of rs3761548 polymorphism was significantly correlated with elevated ischemic stroke susceptibility both at prior and after adjusted by smoking, HBP, DM, TG and HDL-C. Recessive model of rs2232365 polymorphism could elevate the susceptibility of ischemic stroke (OR = 11.962, 95 %CI = 1.144-3.3363; adjusted: OR = 1.876, 95 %CI = 1.016-3.463). Besides, rs3761548 dominant model (OR = 2.757, 95 %CI = 1.379-5.552; adjusted: OR = 2.601, 95 %CI = 1.268-5.336) and rs2232365 recessive model (OR = 3.103, 95 %CI = 1.463-6.583; adjusted: OR = 3.545, 95 %CI = 1.600-7.855) were related to the severity of ischemic stroke. CONCLUSIONS FOXP3 gene rs3761548 and rs2232365 polymorphisms were risk factors for susceptibility and severity of IS.

UI MeSH Term Description Entries

Related Publications

Youpei Wang, and Tiru Shan, and Peipei Mao, and Yi Jiang, and Zhao Wang
December 2025, Annals of medicine,
Youpei Wang, and Tiru Shan, and Peipei Mao, and Yi Jiang, and Zhao Wang
January 2018, Oncotarget,
Youpei Wang, and Tiru Shan, and Peipei Mao, and Yi Jiang, and Zhao Wang
July 2013, Neural regeneration research,
Youpei Wang, and Tiru Shan, and Peipei Mao, and Yi Jiang, and Zhao Wang
January 2022, Frontiers in neuroscience,
Youpei Wang, and Tiru Shan, and Peipei Mao, and Yi Jiang, and Zhao Wang
September 2009, Journal of the neurological sciences,
Youpei Wang, and Tiru Shan, and Peipei Mao, and Yi Jiang, and Zhao Wang
December 2019, Experimental biology and medicine (Maywood, N.J.),
Youpei Wang, and Tiru Shan, and Peipei Mao, and Yi Jiang, and Zhao Wang
January 2022, Neuropsychiatric disease and treatment,
Youpei Wang, and Tiru Shan, and Peipei Mao, and Yi Jiang, and Zhao Wang
September 2011, Journal of the neurological sciences,
Youpei Wang, and Tiru Shan, and Peipei Mao, and Yi Jiang, and Zhao Wang
January 2017, BioMed research international,
Youpei Wang, and Tiru Shan, and Peipei Mao, and Yi Jiang, and Zhao Wang
May 2010, Progress in neuro-psychopharmacology & biological psychiatry,
Copied contents to your clipboard!